Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2003

View Archived Issues

MorphoSys and Schering AG collaboration yields positive animal data

MedImmune and Critical Therapeutics to develop drugs targeting HMGB-1

Fulvestrant at least as effective as anastrozole in advanced breast cancer

Ariad summarizes recent important findings

FDA requests additional information in support of Hemopure BLA

GPC Biotech makes progress on various fronts with 1D09C3

Happy Valley Medical licenses Ceracor to Edwards Lifesciences

NeoGenesis and Amgen form R&D collaboration

Squalamine improves visual outcomes in phase I/II wet AMD study

CV Therapeutics and FDA agree to cancel Ranexa review

Chiron licenses HCV technology to Gilead for drug development efforts

Novel HCV NS3 protease inhibitors under study at BMS

Antibacterial quaternary ammonium salts, their preparation and use reported by Toagosei

JT patent covers new inhibitors of sodium-phosphate cotransporter and their use

Two novel series of lanosterol synthase inhibitors in early development at Roche

New antitumor agents in Kyowa Hakko development pipeline

ARS scientists design GILZ-based peptides for use in cancer, inflammation, etc.

Irreversible inhibition of CYP3A4 described for tabimorelin in humans

Astralis cleared to begin phase I testing of Psoraxine in U.S.

Submission of European MAA, U.S. sNDA for Angiomax

FDA approves Photofrin PDT for high-grade dysplasia in Barrett's esophagus

Novel antibiotics targeting pantothenate kinase

Kirin Brewery licenses antibody technology to Takeda

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...